FGF23 Antibody
-
中文名稱：FGF23兔多克隆抗體
-
貨號：CSB-PA060188
-
規格：￥1090
-
其他：
產品詳情
-
Uniprot No.：
-
基因名：
-
別名：ADHR antibody; FGF-23 antibody; Fgf23 antibody; FGF23_HUMAN antibody; FGFN antibody; Fibroblast growth factor 23 antibody; Fibroblast growth factor 23 C-terminal peptide antibody; Fibroblast growth factor 23 precursor antibody; HPDR2 antibody; HYPF antibody; Phosphatonin antibody; PHPTC antibody; Tumor derived hypophosphatemia inducing factor antibody; Tumor-derived hypophosphatemia-inducing factor antibody
-
宿主：Rabbit
-
反應種屬：Human,Mouse,Rat
-
免疫原：Synthesized peptide derived from the Internal region of Human FGF-23.
-
免疫原種屬：Homo sapiens (Human)
-
標記方式：Non-conjugated
-
抗體亞型：IgG
-
純化方式：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
-
產品提供形式：Liquid
-
應用范圍：WB, IF, ELISA
-
推薦稀釋比：
Application Recommended Dilution WB 1:500-1:2000 IF 1:200-1:1000 ELISA 1:20000 -
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization.
-
基因功能參考文獻：
- Increases in plasma erythropoietin and erythropoietin receptor activation are mechanisms implicated in the increase of plasma FGF23 in acute kidney injury. PMID: 29395333
- The FGF23 increase related to acute kidney injury, especially in more severe stages and in patients without diuresis, is an independent risk factor for mortality. PMID: 30009421
- In patients with Autosomal Dominant Polycystic Kidney Disease, as the disease stage advanced, serum FGF-23 levels increased while s-KL decreased. In ADPKD patients, the effect of serum FGF-23 on the development of AS and atherosclerosis in peripheral vessels is independent of s-KL. PMID: 30064143
- In summary, our results suggest that FGF23 gene polymorphisms are associated with the risk of developing EH in Chinese Han population. PMID: 29336609
- Although there are many studies suggesting the correlation between FGF23 and Insulin resistance (IR) in different populations, this study did not find any statistically significant relationship between IR and FGF23 levels in metabolic syndrome. PMID: 30001211
- Data suggest that intact FGF23 level in plasma is independent predictor of cardiovascular death in patients with heart failure and provides added value to standard of care, natriuretic peptide (NT-proBNP) plasma level, for risk estimation. This study was conducted in Belgium. (FGF23 = fibroblast growth factor 23; NT-proBNP = aminoterminal pro-B-type natriuretic peptide) PMID: 30205090
- In patients with heart failure, higher plasma FGF23 levels were associated with volume overload and increased risk of all-cause mortality and hospitalization. PMID: 29306478
- serum level of FGF-23 was not correlated with a change in bone mineral density of maintenance hemodialysis patients, whereas the serum Klotho protein level was associated with the degree of bone mineral density PMID: 29665846
- Increased insulin resistance in chronic kidney disease is a consequence of the uremic status and is intimately associated with disturbed phosphate metabolism and FGF23. PMID: 29619868
- Increased serum levels of FGF23 were associated with loss of graft function in kidney transplant recipients. PMID: 29528011
- Responses of FGF23 to salt intervention were more prominent in normotensive, older than 60 years, BMI <24 kg/m(2) and salt-resistant individuals. Furthermore, a significant inverse correlation was observed between 24-hour urinary sodium and serum concentrations of FGF23 after adjusting age, sex, BMI and hypertension status. PMID: 29608553
- FGF23 is reduced in subjects with nephrotic syndrome compared to healthy controls. Reduced levels of Vitamin D, and urinary losses may contribute to lower levels of FGF23 in NS. PMID: 28087977
- Pharmacological treatment of hypercalciuric patients resulted in significantly lower urinary calcium excretion, lower serum FGF23, and elevated TP/GFR and serum phosphate concentration, without significant changes in PTH. PMID: 29457024
- Carboxy-terminal fragment of FGF-23 induces heart hypertrophy in sickle cell disease. PMID: 27789679
- prolonged exposure to high apical calcium and calcium hyperabsorption were sensed by CaSR, which, in turn, increased FGF-23 expression to suppress calcium transport PMID: 29317227
- In a Canadian Asian population with CKD, FGF23 levels obtained at 6-monthly intervals for 3 years predicted ESRD and mortality suggesting that it is also a risk marker in Asians PMID: 28743129
- shed alpha-klotho functions as an on-demand non-enzymatic scaffold protein that promotes FGF23 signalling PMID: 29342138
- Long-term supplementation with modest quantities of omega-3 fatty acids does not reduce plasma FGF23 levels when added to cardiovascular medication in post-myocardial patients with chronic kidney disease. PMID: 29137111
- A decrease in serum FGF23 and hepcidin levels was observed in chronic hemodialysis patients treated with lanthanum carbonate. PMID: 27928636
- serum FGF23 levels were significantly higher and soluble Klotho levels significantly lower in the autosomal-dominant polycystic kidney disease group than in the non-diabetic chronic kidney disease group matched for estimated glomerular filtration rate PMID: 27450645
- Higher serum fibroblast growth factor 23 concentration was associated with kidney function decline, height-adjusted total kidney volume percentage increase, and death in patients with autosomal dominant polycystic kidney disease. PMID: 28705885
- This study indicates a possible mechanism by which excessive levels of FGF23 are involved in endothelial thrombomodulin disruption, which has been implicated as a potential cardiovascular risk factor in patients with chronic kidney disease, especially in hemodialysis patients PMID: 28834363
- Novel relationships were identified between higher plasma FGF23 concentrations and absence of APOL1 renal-risk genotypes with higher mortality in African Americans with diabetes. PMID: 29113983
- FGF23 is an integral part of a complex pathway, associated with higher cardiac mass in African-Americans males with excess adiposity. PMID: 28456498
- found no independent association between FGF-23 and cardiac changes. LVH remains the most common cardiac change seen in children with CKD PMID: 28402974
- Fibroblast Growth Factor-23 was higher in alcoholics than in controls, especially among cirrhotics, and soluble alpha Klotho levels were also higher among cirrhotics. PMID: 28651327
- Dietary factors other than phosphate are associated with FGF23 levels in young adults. PMID: 27942978
- Novel CLCN5 (c.1205G>A, p.W402*) and FGF23 (c.526C>G, p.R176G) mutations were found in two patients from the remaining two families PMID: 28383812
- Review/Meta-analysis: individuals with increased plasma FGF23 levels might suffer a higher risk of all-cause mortality and cardiovascular mortality. PMID: 28411494
- review article will discuss the current experimental and clinical evidence regarding the role of FGF23 in physiology and pathophysiology of CKD and its associated complications with an emphasis on CVD. PMID: 28535521
- In Chinese patients with type 2 diabetes, serum FGF23 levels were independently and positively correlated with the presence of lower extremity atherosclerotic disease. PMID: 28619026
- studied biomarkers do not predict arrhythmia recurrence after catheter ablation. Left atrial voltage is an independent predictor of recurrence, whether the left atrium is mapped in atrial fibrillation or sinus rhythm PMID: 29293545
- A statistically significant positive correlation was found between s-Klotho and FGF23 (r=0.768; p=0.001), and between FGF23 levels and urinary albumin creatinine ratio (r=0.768; p=0.001). PMID: 27323770
- There may be positive dose-response predictive effects of FGF23 on all-cause mortality, cardiovascular disease, and renal events in patients with chronic kidney disease.[meta-analysis] PMID: 28006765
- Circulating FGF23 and inflammatory cytokines are correlated with varying levels of chronic kidney disease. PMID: 27836924
- study indicated that serum FGF-23 level could be served as the utility in the early detection of women with low bone mass. PMID: 28464278
- Newly diagnosed Lupus nephritis (LN) patients demonstrated elevated FGF23 levels that were positively correlated to urinary MCP1, independently of vitamin D levels and kidney function. If FGF23 may predict clinical outcomes in LN warrants further evaluation. PMID: 28063327
- there is a strong relationship between iron and FGF23 physiology; C-terminal FGF23 may have a role in mortality in kidney transplant recipients PMID: 28774998
- FGF23 counteracts osteogenic conversion of vascular smooth muscle cells as a part of a compensatory mechanism to mitigate vascular calcification PMID: 27599364
- intact FGF23 from loss of function mutants bypasses the endoplasmic reticulum/Golgi quality control system to the circulation of hyperphosphatemic familial tumoral calcinosis patients by an unknown pathway. PMID: 26620085
- AN69ST-continuous hemodiafiltration can be a novel FGF-23 lowering therapy for acute illnesses requiring acute blood purification. PMID: 28164555
- FGF23 and its co-receptor klotho play an important role in bone mineral and vitamin D metabolism. In chronic kidney disease, disturbances in bone metabolism increase cardiovascular risk. FGF23 levels are very high in chronic kidney disease and may contribute to vascular calcification and other cardiovascular problems. Review. PMID: 27118192
- can directly stimulate hepatic secretion of inflammatory cytokines PMID: 27457912
- Elevated levels of interleukin-6, C-reactive protein, and FGF23 are independent risk factors for mortality in chronic kidney disease. PMID: 28017325
- Main demonstrable effect of FGF23 in the setting of preserved renal function is suppression of 1,25-dihydroxyvitamin D3 rather than stimulation of renal phosphate excretion. PMID: 27370409
- An overview of FGF23 biology and physiology is provided, clinical outcomes that have been associated with FGF23 are summarized, potential mechanisms for these observations are discussed. PMID: 28715994
- Sclerostin levels in KTR are normal and influenced more by bone turnover than by eGFR. Its involvement with other hormones of mineral homeostasis (FGF23/Klotho and Vitamin D) is part of the sophisticated cross-talk between bone and the kidney PMID: 28558021
- High serum FGF23 expression is associated with acute decompensated heart failure. PMID: 26666498
- High FGF-23 expression is associated with cardiovascular disease. PMID: 26888181
- high i-FGF23 levels may be associated with prolongation of low levels of ferritin, resulting in increased usages of iron supplementation in HD patients PMID: 28475601
顯示更多
收起更多
-
相關疾病：Hypophosphatemic rickets, autosomal dominant (ADHR); Tumoral calcinosis, hyperphosphatemic, familial (HFTC)
-
亞細胞定位：Secreted. Note=Secretion is dependent on O-glycosylation.
-
蛋白家族：Heparin-binding growth factors family
-
組織特異性：Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts).
-
數據庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
